Continuous Renal Replacement Therapy Market Size by 2030

[Research Report] The continuous renal replacement therapy market size is projected to grow from US$ 1.42 billion in 2022 to US$ 2.75 billion by 2030. The market is estimated to register a CAGR of 8.7% from 2022 to 2030.

Market Insights and Analyst View:

This report includes growth prospects owing to the current continuous renal replacement therapy market trends and their foreseeable impact during the forecast period.

Continuous renal replacement therapy (CRRT) is a life-saving intervention for patients suffering severe acute kidney injury (AKI), fluid overload, and uremia with potentially fatal metabolic abnormalities. Factors such as the increased demand for pediatric CRRT devices and the high prevalence of chronic diseases leading to kidney diseases propel the continuous renal replacement therapy market growth. However, a significant chance of a major adverse kidney event (MAKE) limits the market growth.

Market Drivers:

High Incidence of Chronic Diseases Leading to Kidney Diseases

1 in 10 people globally is affected by chronic kidney disease (CKD), which is a common and life-threatening condition. From 2015 to 2019, diabetes and high blood pressure were the two major causes of kidney failure in 75% of the total failure cases. According to estimates released by the National Kidney Foundation in 2020, in the US ~30% of the diabetic population above 20 years of age is at risk of developing CKD in their lifetime. Moreover, this disease caused more deaths than prostate cancer or breast cancer in 2020, and it is an under-recognized emergency health disorder. 1 in 3 American adults (i.e., ~80 million people) is at risk of CKD, which is now identified as a clear risk factor for AKI. Decreased glomerular filtration rate (GFR) and increased proteinuria are strongly associated with an AKI.

According to the National Institute of Health, the occurrence of AKI is rising in developed countries. Its prevalence in hospital inpatients is predicted to reach 15%, and it is higher in critically ill patients i.e., 60%. An AKI incidence in inpatients across the world ranges from 0.7% to 31%; patients in intensive care units (ICUs) experience an incidence of more than 50%. A range from 3% to 13% of patients having AKI need RRT and 40% of these patients are estimated to need CRRT for more than 90 days. Thus, the high prevalence of chronic diseases leading to kidney diseases boosts the continuous renal replacement therapy market growth.

Major ill effects associated with CRRT include hypotension, tachycardia, and other arrhythmias, which may adversely affect the patient's condition or impede their recovery. Furthermore, the CRRT circuit might facilitate the faster clearance of micronutrients, trace elements, and/or therapeutic medicines, which can lead to low or irregular concentrations in blood and tissues, thereby causing adverse effects and/or loss of therapeutic effect. Thus, the adverse effects restrict the continuous renal replacement therapy market.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Continuous Renal Replacement Therapy Market: Strategic Insights

Market Size Value in	US$ 1.42 billion in 2022
Market Size Value by	US$ 2.75 billion by 2030
Growth rate	CAGR of 8.7% from 2022 to 2030
Forecast Period	2022-2030
Base Year	2022

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

 Speak to Analyst

Report Segmentation and Scope:

The continuous renal replacement therapy market analysis has been carried out by considering the following segments: product, modality, and end user.

Segmental Analysis:

The continuous renal replacement therapy market, by product, is segmented into dialysates and replacement fluids, disposables, bloodline sets and tubes, CRRT systems, and hemofilters. The CRRT systems segment accounted for the largest share of the market in 2022. The hemofilters segment is anticipated to register the highest CAGR in the market during 2022–2030.

Continuous Renal Replacement Therapy Market, by Product – 2022 and 2030

Access Data

By modality, the continuous renal replacement therapy market is segmented into continuous venovenous hemofiltration (CVVH), continuous venovenous hemodiafiltration (CVVHDF), continuous venovenous hemodialysis (CVVHD), and slow continuous ultrafiltration (SCUF). The continuous venovenous hemofiltration (CVVH) segment held the largest share of the market in 2022. The market for the continuous venovenous hemodiafiltration (CVVHDF) segment is expected to register the highest CAGR during 2022–2030.

By end user, the continuous renal replacement therapy market is segmented into hospitals, ambulatory care centers, home care, and others. In 2022, the hospitals segment dominated the continuous renal replacement therapy market share. However, the home monitoring segment is expected to register the highest CAGR during 2022–2030.

Regional Analysis:

The scope of the continuous renal replacement therapy market report encompasses North America (US, Canada, and Mexico), Europe (Spain, UK, Germany, France, Italy, and Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

In terms of revenue, in 2022, North America dominated the continuous renal replacement therapy market share. The market in Asia Pacific is anticipated to register the highest CAGR during 2022–2030. The continuous renal replacement therapy market in Asia Pacific is growing with the improving healthcare infrastructure and the adoption of innovative CRRT technologies, both of which can be associated with rising healthcare expenditure. Additionally, strategic initiatives by the market players to expand their presence in Asia Pacific, such as collaborations with local healthcare providers, favor the market growth in the region.

Competitive Landscape and Key Companies:

The continuous renal replacement therapy market report is focused on prominent players in the market such as Baxter International Inc, Asahi Kasei, Fresenius Medical Care, Medica S.p.A., Medtronic Plc, B. Braun, Nikkiso Co Ltd, Toray Medical Co Ltd, Infomed SA, and Quanta Dialysis Technologies Inc. The continuous renal replacement therapy market forecast can help stakeholders plan their growth strategies. These companies focus on launching new technologies, upgrading existing products, and expanding their businesses to meet the growing consumer demand worldwide.

• In April 2022, the US Food and Drug Administration (FDA) provided 510(k) clearance for the ST Set by Baxter International Inc. for its use in continuous renal replacement therapy (CRRT). The ST Set is a pre-connected, disposable, extracorporeal (outside the body) circuit that provides blood purification through a semipermeable membrane to be used with the PrisMax or Prismaflex control units (monitors).
• In March 2022, Nipro Medical Corporation (Nipro), a leading manufacturer and supplier of renal, vascular, and medical-surgical products, announced the commercial launch of the SURDIAL DX Hemodialysis System in the US. SURDIAL DX is a state-of-the-art hemodialysis system designed to create an optimal dialysis treatment experience for patients and clinicians. Manufactured in Japan, the product is based is based on over 35 years of expertise in renal device innovation at Nipro’s parent company, Nipro Corporation.